Wed, Mar 4, 2015, 11:52 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Fibrocell Science, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dmesshian dmesshian Feb 23, 2012 11:21 AM Flag

    For All of You BOTOX Pumpers - Good Read!

    You state: "You are an uninformed idiot. In 2007, there were less than 30,000 cosmetic procedures done in the UK. Your statistics of 7000 procedures over 7 years says that Isolagen did about 1000 procedures per year or a little more than 3% of the 2007 market."


    The "serious flaw" in your argument is that, during Laviv's marketing in Europe, they NEVER MADE ANY MONEY!
    How can a small capitalized concern -- as YOU state -- garner 3% of the market in Europe and not turn a profit??!!
    PLUS, they had to run home to the U.S. after the class action lawsuit bug hit; that was settled by their insurer.

    Your follow up statement: ***..." laViv can get to 3% of this market, that will be more than 400,000 procedures a year or more than 1B dollars in revenue. Give it a few years. "***

    Yeah, Allergan, Medicis, JNJ, and a gaggle of smaller players will roll-over and allow FCSC-laviv to take away "1 billion$$$$" in market share in an "Aesthetic market" that fights viciously -- and leaves "blood in the water" over "1 basis point"????
    What are YOU drinking or eating to make such a... "haphazard statements" -- for a product -- Laviv -- that has never turned a profit -- not even a penny -- in it's 30 years of existence!!!!

    What are ya smokin' pal? You obviously have very limited knowledge of the "competitive environment".
    And it shows... MSSR. PUMPER, eh...

5.65+0.5000(+9.71%)Mar 4 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.